078160.KQ
MEDIPOST Co., Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 8,690.00
−0.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 74.8B | 73.7B | 70.7B | 68.6B | 64.2B |
| Cost of Revenue | 28.1B | 30.6B | 26.5B | 28.5B | 27.0B |
| Gross Profit | 46.7B | 43.1B | 44.1B | 40.2B | 37.2B |
| Operating Expenses | |||||
| R&D Expense | 81.4B | 71.3B | 54.6B | 29.2B | 19.1B |
| SG&A Expense | 28.7B | 22.8B | 20.7B | 19.8B | 35.0B |
| General & Admin Expense | 7.6B | 9.6B | 9.2B | 8.5B | 8.2B |
| Selling & Marketing Expense | 10.6B | 13.2B | 11.5B | 11.3B | 14.8B |
| Other Expenses | 43.4B | 17.0B | 17.4B | 16.3B | 601.2M |
| Total Operating Expenses | 125.6B | 111.1B | 92.7B | 65.3B | 54.7B |
| Cost and Expenses | 150.5B | 141.6B | 119.2B | 93.8B | 81.7B |
| Operating Income (EBIT) | (46.5B) | (68.0B) | (48.5B) | (25.1B) | (17.5B) |
| Non-Operating | |||||
| Interest Income | 3.2B | 2.1B | 3.4B | 3.9B | 1.4B |
| Interest Expense | 11.2B | 543.6M | 499.3M | 6.4B | 8.3B |
| Net Interest Income | (8.0B) | 1.6B | 2.9B | 3.9B | (6.8B) |
| Other Non-Op Income/Expense | 15.9B | (17.9B) | (14.4B) | 29.5B | 23.9B |
| Non-Operating Income (excl Interest) | 9.0B | — | 13.9B | (35.9B) | (32.2B) |
| EBT (Pre-Tax Income) | (30.6B) | (85.9B) | (62.9B) | 4.4B | 19.2B |
| Income Tax Expense | (6.9B) | 118.6M | 446.1M | (536.6M) | 4.4B |
| Bottom Line | |||||
| Net Income | (23.1B) | (85.4B) | (62.5B) | 5.8B | 3.1B |
| Earnings from Cont. Ops | (23.7B) | (86.0B) | (63.4B) | 5.0B | 2.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (57.8B) | (85.4B) | (62.5B) | 5.8B | 3.1B |
| Per Share | |||||
| Basic EPS | (₩704) | (₩2,193) | (₩1,833) | ₩287 | ₩167 |
| Diluted EPS | (₩1,577) | (₩2,193) | (₩1,834) | ₩231 | ₩145 |
| Revenue Per Share | ₩1,915 | ₩1,879 | ₩2,072 | ₩3,373 | ₩3,495 |
| Shares | |||||
| Basic Shares Outstanding | 39.1M | 39.2M | 34.1M | 20.3M | 18.4M |
| Diluted Shares Outstanding | 51.8M | 39.2M | 34.1M | 25.3M | 21.1M |
| Profitability Metrics | |||||
| EBITDA | (75.6B) | (63.2B) | (56.4B) | (19.4B) | (12.1B) |
| D&A | 5.2B | 6.0B | 6.0B | 5.9B | 5.4B |
| EBIT | (80.8B) | (69.2B) | (62.4B) | (25.3B) | (17.4B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026